Companies · Biotech

Psycheceutical Bioscience, Inc.

Fort Lauderdale · Biotech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Psycheceutical Bioscience, Inc. — recommendation, valuation, rhythm, risks.
$7.3M
Total raised · real
5
Rounds
1.0×
Latest step-up
Top 18%
Sector rank · raised
Seed
Latest stage · inferred · Thu Jun 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Psycheceutical Bioscience, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.04× the median modeled value of Seed Biotech companies in 2022–2024 (6 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.0 yr ago; this sector typically re-raises about every 11 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech

Psycheceutical Bioscience, Inc. is one of 233 Biotech companies tracked from Fort Lauderdale. By capital raised it ranks in the upper tier (ahead of 83% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
1
Investors (latest)
2024-06-20
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2012-07-01 Raised $3.1M (real) Modeled valuation $137M (est)$3.1M$137MSeed2012Seed · 2012-07-01 Raised $3.0M (real) Modeled valuation $133M (est)$3.0M$133MSeed2012Seed · 2021-11-29 Raised $771K (real) Modeled valuation $16M (est)$771K$16MSeed2021Seed · 2022-03-01 Raised $360K (real) Modeled valuation $6.4M (est)$360K$6.4MSeed2022Pre-Seed · 2022-03-01 Raised $100K (real) Modeled valuation $2.0M (est)$100K$2.0MPre-Seed2022Seed · 2024-06-20 Raised $100K (real) Modeled valuation $492K (est)$100K$492KSeed2024+$3.0M+$771K+$360K+$100K+$100KCumulative $7.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.1M · 2012
Seed extension$3.0M · 2012
Seed extension$771K · 2021
Seed extension$360K · 2022
Bridge · Seed-stage$100K · 2022smaller follow-on
Seed extension$100K · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$492K
Base estimate est.
$72K
Conservative case
$1.3M
Upside case
$500K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $137.3M · 2012-07-012012Seed · modeled $133.2M · 2012-07-01Seed · modeled $15.6M · 2021-11-29Seed · modeled $6.4M · 2022-03-01Pre-Seed · modeled $2.0M · 2022-03-01Seed · modeled $492K · 2024-06-202024
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
2.0 yr
Elapsed time used
2.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
29 mo
Avg between rounds
$612K/yr
Capital velocity
14.0 yr
On record since
2012
First round
6
Rounds on file
How it compares to the market

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.9× of median
This company$7.3M
Sector median$7.8M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.1× of median
This company$100K
Sector median$1.2M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$492K
Sector median$56.1M

Raised more than 83% of sector peers (real $). Modeled value above 68% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #6 of 6.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$1.0M$10.0MCapital raised (log)Yemaachi · Seed Raised $3.0M · modeled $51.0M (est)INVO Bioscience, Inc. · Seed Raised $7.8M · modeled $29.2M (est)General Genomics Inc. · Seed Raised $4.0M · modeled $14.1M (est)MET Biotechnology Inc. · Seed Raised $2.0M · modeled $12.3M (est)J3 Bioscience, Inc. · Seed Raised $5.5M · modeled $7.4M (est)Psycheceutical Bioscience, Inc. (this company) Raised $7.3M · modeled $492K (est)Psycheceutical Bioscience, Inc.
CompanyStageRaised · realValue · estvs peer med.
YemaachiSeed$3.0M$51.0M3.87×
INVO Bioscience, Inc.Seed$7.8M$29.2M2.21×
General Genomics Inc.Seed$4.0M$14.1M1.07×
MET Biotechnology Inc.Seed$2.0M$12.3M0.93×
J3 Bioscience, Inc.Seed$5.5M$7.4M0.56×
Psycheceutical Bioscience, Inc. this companySeed$7.3M$492K0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.1M2012-07-01$15.5M$137.3M85%
Seed$3.0M2012-07-01$15.0M$133.2M85%
Seed$771K2021-11-29$3.9M$15.6M90%
Seed$360K2022-03-01$1.8M$6.4M90%
Pre-Seed$100K2022-03-01$556K$2.0M90%
Seed$100K2024-06-20$500K$492K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.1M2012-07-01
    • First recorded raise — entered as Seed.
  2. Seed$3.0M2012-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  3. Seed$771K2021-11-29
    • Raised again after 113 mo — slower than the ~11 mo sector norm.
    • Round 3.9× smaller than the prior — bridge or down round.
    • Revenue band moved No revenue → $0–$1M.
    • Switched to Rule 506(b) (was Rule 06).
    • 13 investors on this round.
  4. Seed$360K2022-03-01
    • Came back fast: 3 mo vs the ~11 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  5. Pre-Seed$100K2022-03-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.6× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  6. Seed$100K2024-06-20
    • Raised again after 28 mo — slower than the ~11 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2026 ~Q4
Modeled next raise · ~29mo cadence
$100K
Modeled next size est.range $100K$160K
1.0×
Last step-up
$612K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Bruce Cassidy4 other2021-11
Chad Harman2 other2021-11
Michael Hlavsa1 other2021-11
Michael Zapolin1 other2021-11
W. Keith Webb1 other2012-07
Alan Keith Parks2012-07
Julian Bailes2024-06
Michael Gurin2021-11
Michael Keith Donaghy2012-07
Neilank Jha2024-06
Registry & provenance

Psycheceutical Bioscience, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1310291
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
INVO Bioscience, Inc.BiotechSeed$7.8M$29.2Msame sector · same stage
J3 Bioscience, Inc.BiotechSeed$5.5M$7.4Msame sector · same stage
iGenomX International Genomics CorpBiotechSeed$5.1M$66.7Msame sector · same stage
Orpheus Bioscience, Inc.BiotechSeed$4.4M$140.2Msame sector · same stage
General Genomics Inc.BiotechSeed$4.0M$14.1Msame sector · same stage
Meridian Biotech, LLCBiotechSeed$3.9M$88.0Msame sector · same stage
Ambra Bioscience LLCBiotechSeed$3.8M$46.6Msame sector · same stage
KelSie Biotech CorpBiotechSeed$3.3M$40.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Psycheceutical, Inc.PharmaceuticalsPre-Seed$9.2M86%
Psyched Wellness Ltd.HealthtechSeries A$13.6M83%
Los Angeles Biosciences, Inc.Biotech / PharmaSeries A$16.3M83%
Ambra Bioscience LLCBiotechSeed$46.6M82%
Venus Health Science, LLCHealthtechSeed$6.3M81%
CMTx Biotech, Inc.BiotechPre-Seed$27.6M81%
Elephas Biosciences CorpBiotech / PharmaSeries C$560.1M81%
Mindhealth Biomed Corp.OtherPre-Seed$15.9M80%
Frequently asked
How much funding has Psycheceutical Bioscience, Inc. raised?
Psycheceutical Bioscience, Inc. has raised approximately $7.3M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Psycheceutical Bioscience, Inc.'s estimated valuation?
Provath's modeled valuation for Psycheceutical Bioscience, Inc. is approximately $492K (modeled range $72K–$1.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Psycheceutical Bioscience, Inc. at?
Psycheceutical Bioscience, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Thu Jun 20.
What does Psycheceutical Bioscience, Inc. do and where is it based?
Psycheceutical Bioscience, Inc. operates in the Biotech sector, based in Fort Lauderdale.
Explore related

See where Psycheceutical Bioscience, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Psycheceutical Bioscience, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.